Gloucestershire Health and Care- NHS Trust logo
with you, for you
Responses > Analysis on the Uptake of Biosimilar Use for Ustekinumab

Freedom of Information request Analysis on the Uptake of Biosimilar Use for Ustekinumab

Response published: 2 April 2025

FOI Request

I am conducting an analysis on the uptake of biosimilar use for Ustekinumab. I would be grateful if you could please tell me how many patients were treated with Ustekinumab (for any disease) for the three-month period specified within the questions. Q1 – How many patients were treated with Ustekinumab and its biosimilars (for any disease) from the start of October 2024 to the end of December 2024? Please use the latest available 3 months if October to December is not available and specify which 3 months have been used. Q2 – How many patients were treated with Stelara and its biosimilars (for any disease) in the months October 2024, November 2024, and December 2024? Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

FOI Response

Freedom of Information Request – Ref: FOI 397-2025

Thank you for your recent Freedom of Information request. Please find our response below.

You asked:

I am conducting an analysis on the uptake of biosimilar use for Ustekinumab.

I would be grateful if you could please tell me how many patients were treated with Ustekinumab (for any disease) for the three-month period specified within the questions.

I have provided the questions below with response grids in appendix A (see below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals within the organisation.

Q1 – How many patients were treated with Ustekinumab and its biosimilars from the following departments (for any disease) from the start of October 2024 to the end of December 2024?

Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

Drug Name Dermatology Gastroenterology Rheumatology
Ustekinumab (Stelara)
Ustekinumab (Pyzchiva)
Ustekinumab (Uzpruvo)
Ustekinumab (Wezenla)

 

Q2 – How many patients were treated with Stelara and its biosimilars (for any disease) in the months October 2024, November 2024, and December 2024?

Please use the latest available 3 months if October to December is not available and specify which 3 months have been used.

Drug Name October 24 November 24 December 24
Ustekinumab (Stelara)
Ustekinumab (Biosimilars)

Our response:

The Trust does not provide the services mentioned on your request and does not use Stelara and Biosimilars for any disease. Please contact Gloucestershire Hospitals NHS Foundation Trust.

Next steps:

Should you have any queries in relation to our response, please do not hesitate to contact us. If you are unhappy with the response you have received in relation to your request and wish to ask us to review our response, you should write to:

Louise Moss
Head of Legal Services / Associate Director of Corporate Governance
c/o Gloucestershire Health and Care NHS Foundation Trust
Edward Jenner Court
1010 Pioneer Avenue
Gloucester Business Park
Brockworth, GL3 4AW
E-mail: louise.moss@ghc.nhs.uk

If you are not content with the outcome of any review, you may apply directly to the Information Commissioner’s Office (ICO) for further advice/guidance. Generally, the ICO will not consider your case unless you have exhausted your enquiries with the Trust which should include considering the use of the Trust’s formal complaints procedure. The ICO can be contacted at: The Information Commissioner’s Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.